- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07896252
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients (AERODUO-2)
Randomized, Double-Blind, Placebo-Controlled, 14-Day Treatment, 2-Period Crossover Trial Evaluating the Lung Function Response After Treatment With Inhaled LABA and LAMA Monotherapies and Their Combination AERO-007 Administered Via Nebulization in Participants With Chronic Obstructive Pulmonary Disease (COPD) (AERODUO-2 Trial)
This is a phase 2b, randomized, double-blind, placebo-controlled, dose-ranging,14-day dosing, 2-period crossover study in participants with chronic obstructive pulmonary disease (COPD).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Combination of a long-acting beta-agonist (LABA) bronchodilator and a long-acting muscarinic antagonist (LAMA) bronchodilator is the preferred choice for initial therapy for patients with chronic obstructive pulmonary disease (COPD). Although there are currently multiple LABA+LAMA combination bronchodilators available in metered dose inhalers (MDIs), dry powder inhalers (DPI), and soft mist inhalers (SMI), a significant percentage of COPD patients, generally high risk and older patients, do not receive optimal benefit from inhalers.
Nebulized delivery provides an effective alternative where disease management is sub optimal. To date there are no approved LABA+LAMA combinations available by nebulization.
AERO-007 is a propriety inhalation solution formulation of fixed-dose combination of LABA+LAMA (indacaterol, AERO-001 and glycopyrrolate, AERO-002) for delivery in a general purpose nebulizer device. A phase 2a, single-dose, dose-ranging study of AERO-007 has been completed in participants with COPD at two dose levels (100/50 µg and 200/100 µg). AERO-007 at both low and high doses was well tolerated with robust, clinically meaningful and statistically significant bronchodilation with rapid onset of action that was sustained for 24 hours.
The objective of this phase 2b study is to determine the optimal doses of the monotherapy components of AERO-007 and to assess the safety, PK and bronchodilation profile of AERO-007 following 14 days of dosing in participants with COPD.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Study Director Medical Director
- Número de telefone: +1-858-750-4717
- E-mail: info@aerorxtherapeutics.com
Locais de estudo
-
-
-
London, Reino Unido
- Recrutamento
- Parexel
-
Manchester, Reino Unido
- Recrutamento
- Medicines Evaluation Unit
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Male or female aged 40 to 75 years, inclusive, at the time of informed consent
-
Clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report, 2026 for at least 12 months prior to Screening Visit 1
-
Post-bronchodilator spirometry (after 10 to 30 minutes following 4 puffs of albuterol via MDI with a spacer) at Screening Visit 2 demonstrating the following:
- FEV1 > 40 and < 80% of predicted normal (using the Global Lung Function Initiative [GLI] 2012 reference values)
- FEV1/forced vital capacity (FVC) ratio < 0.70
- ≥ 150 mL increase from pre-bronchodilator FEV1 following 4 puffs of albuterol
-
Ability to change current COPD therapy and discontinue long-acting bronchodilators, if applicable, for the duration of the trial and short-acting bronchodilators for 8 hours prior to dosing at each Treatment Visit
-
Current or former-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, 10 packs/day for 1 year)
-
Ability to perform reproducible spirometry according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines
-
Female participants of childbearing potential must not be pregnant, breast feeding or lactating and heterosexual female participants of childbearing potential must agree to use, with their partner, a male condom plus an approved method of highly effective birth control from the time of informed consent and for 30 days following the last administered dose
-
Female participants of childbearing potential must have a negative serum or urine pregnancy test at Screening Visit 1 and a negative urine pregnancy test prior to dosing at each Treatment Visit
-
Male participants who are sexually active with a female partner of childbearing potential must use, with their partner, a male condom plus an approved method of highly effective contraception from the time of informed consent and for 30 days following the last administered dose
-
Participants must agree not to donate semen or ova/oocytes from the time of informed consent and for 30 days following the last administered dose
-
Willing and able to provide written informed consent
Exclusion Criteria:
- Current evidence or recent history of significant comorbidities; including cardiovascular disease (such as myocardial infarction, cardiac failure, uncontrolled hypertension, or life-threatening arrhythmias), uncontrolled diabetes, neurologic, psychiatric, hepatic, renal, immunological, or hematological conditions within the last 6 months prior to Screening Visit 1
- Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV) type 1 and/or 2 antibodies at Screening Visit 1
- Lower respiratory tract infection within 6 weeks prior to Screening Visit 1
- Recent history of hospitalization due to an exacerbation of airway disease or acute worsening of COPD requiring antibiotic or systemic corticosteroid treatment within 6 months prior to Screening Visit 1
- Other respiratory disorders: Current diagnosis of predominant asthma, lung cancer, bronchiectasis, interstitial lung disease, tuberculosis, pulmonary hypertension, or other non-specific pulmonary diseases
- Prior lung volume reduction surgery or history of chest/lung irradiation
- Daily oxygen therapy for > 12 hours per day
- Body mass index >35 kg/m2
- Abnormal and clinically significant 12-lead ECG findings at Screening Visit 1
- Current or recent history of medical conditions that are contraindicated for use of an inhaled LAMA (such as urinary retention or bladder neck obstruction type symptoms, prostatic hypertrophy, or narrow-angle glaucoma) within the last 6 months prior to Screening Visit 1
- Current or recent history (previous 12 months) of excessive use or abuse of alcohol (males >21 units per week and females >14 units per week)
- Current evidence or history (within the past 2 years) of abusing legal drugs or use of illegal drugs or substances
- Donation of 450 mL of blood within 8 weeks of Screening Visit 1
- Major surgery (requiring general anaesthesia) within 6 weeks prior to Screening Visit 1, or planned surgery through the EOS Visit
- History of malignancy of any organ system, except for localized skin cancers, within 5 years prior to Screening Visit 1
- History of intolerance or hypersensitivity to any of the ingredients in the formulation for AERO-001, AERO-002, AERO-007, or other aerosol medications
- Participation in another investigational drug trial within 30 days of the last dose, 5 half-lives or twice the duration of the biological effect, whichever is longer, prior to Screening Visit 1
- History or high risk of noncompliance with trial visits and procedures or unsuitable for entry into the trial at the discretion of the Investigator
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
|
Double-blind |
|
Experimental: Aero-001 dose baixa
|
Double-blind |
|
Experimental: Aero-001 Alta dose
|
Double-blind |
|
Experimental: Aero-002 Doses baixas
|
Double-blind |
|
Experimental: Aero-002 Alta dose
|
Double-blind |
|
Experimental: AERO-001 medium dose
|
Double-blind |
|
Experimental: AERO-002 medium dose
|
Double-blind |
|
Experimental: AERO-007
|
Double-blind |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Bronchodilation - FEV1
Prazo: Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
|
Change from baseline in FEV1 at 24 hours post-dose on Days 1 and 14
|
|
Bronchodilation - FEV AUC
Prazo: Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
|
Change from baseline in FEV1 AUC(0-24 hours) on Days 1 and 14
|
|
Bronchodilation - Peak FEV1
Prazo: Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
|
Peak change in FEV1 within 4 hours post-dose on Days 1 and 14
|
|
Bronchodilation - time to onset of FEV1 >100mL
Prazo: Change in FEV1 >100mL from pre-dose on Days 1 and 14
|
Change in FEV1 >100mL from pre-dose on Days 1 and 14
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pharmacokinetics - Cmax
Prazo: 0-24 hours on Days 1 and 14
|
Cmax (maximum plasma concentration) |
0-24 hours on Days 1 and 14
|
|
Pharmacokinetics - AUC
Prazo: AUC(0-6 hours) on Days 1 and 14
|
AUC (area under the plasma concentration) |
AUC(0-6 hours) on Days 1 and 14
|
|
Pharmacokinetics - Tmax
Prazo: Tmax on Days 1 and 14
|
Tmax (time to maximum concentration) |
Tmax on Days 1 and 14
|
|
Treatment-emergent adverse events (TEAEs)
Prazo: Up to approximately Day 14
|
Number of participants with TEAEs |
Up to approximately Day 14
|
|
Blood Pressure
Prazo: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in Blood Pressure |
Up to approximately Day 14
|
|
Heart Rate
Prazo: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in Heart Rate |
Up to approximately Day 14
|
|
12-lead ECG - QT Interval corrected for Heart Rate Using Fridericia's Formula (QTcF)
Prazo: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in QTcF |
Up to approximately Day 14
|
|
Clinical laboratory - Hematology
Prazo: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in hematology parameters |
Up to approximately Day 14
|
|
Clinical laboratory - Blood Chemistry
Prazo: Up to approximately Day 14
|
Number of participants with markedly abnormal changes in blood chemistry parameters |
Up to approximately Day 14
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- AERO-007-02
- 2026-527150-39 (Número EudraCT)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .